文献速递产科

氨氯地平与硝苯地平缓释剂治疗产后高血压:一项非劣效性随机对照试验

Amlodipine versus nifedipine ER for the management of postpartum hypertension: a noninferiority randomized controlled trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-12-09

这项实用性随机对照非劣效性试验将产后高血压患者分配至氨氯地平或硝苯地平缓释剂组,主要结局为从分娩至出院的住院时间,非劣效界值为24小时。氨氯地平组住院时间不劣于硝苯地平缓释剂组(意向治疗分析Wilcoxon伪中位数氨氯地平=73.5小时,硝苯地平缓释剂=72.0小时,95%CI -8.00至6.00)。氨氯地平因副作用停药显著更少(氨氯地平n=0,硝苯地平缓释剂n=7(10.1%),p=.02)。

要点

  • 氨氯地平组产后住院时间不劣于硝苯地平缓释剂组(伪中位数73.5小时 vs 72.0小时,95%CI -8.00至6.00)。
  • 氨氯地平因副作用停药显著少于硝苯地平缓释剂(n=0 vs n=7(10.1%),p=.02)。
  • 两组需额外降压药、患者报告副作用及母乳喂养结局无差异,但氨氯地平组低血压和心动过速更少见。

核心结论

  • 以产后住院时间中位数定义,氨氯地平治疗产后高血压不劣于硝苯地平缓释剂。
  • 两组副作用发生率相似,但因副作用停药率有统计学显著差异。

研究设计与样本

  • 实用性随机对照非劣效性试验,2021年4月至2022年12月筛查7618例患者,随机175例,其中132例符合启动降压药标准。
  • 主要结局为从分娩至出院的时间,非劣效界值为24小时;样本量132例以达到80%把握度,双侧α=0.05。
  • 进行了意向治疗和符合方案分析;预设次要结局包括需额外降压药、副作用、停药、母乳喂养满意度及再入院率;事后分析从用药开始至出院时间。

主要发现

  • 意向治疗分析Wilcoxon伪中位数住院时间:氨氯地平=73.5小时,硝苯地平缓释剂=72.0小时,95%CI -8.00至6.00。
  • 符合方案队列中从用药开始至出院时间:氨氯地平=45.0小时,硝苯地平缓释剂=45.5小时,95%CI -8.00至13.00。
  • 因副作用停药:氨氯地平n=0,硝苯地平缓释剂n=7(10.1%),p=.02。
  • 两组需额外降压药、患者报告副作用及母乳喂养结局无差异;氨氯地平组低血压和心动过速更少见;再入院率相似。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postpartum hypertension is an increasingly prevalent problem and optimizing its treatment is imperative in reducing maternal morbidity and improving long-term health outcomes. Despite this, data on treatment of postpartum hypertension is limited. While most available studies focus on labetalol and nifedipine ER, these medications are not frequently used for hypertension treatment in the non-obstetric setting. As we aim to establish best practices for managing postpartum hypertension, use of more commonly encountered antihypertensives should be evaluated. OBJECTIVE: To evaluate the use of amlodipine for the treatment of postpartum hypertension, as assessed by postpartum length of stay. STUDY DESIGN: In a pragmatic, randomized controlled noninferiority trial, patients were assigned to amlodipine or nifedipine ER for treatment of postpartum hypertension. The primary outcome was time from delivery until discharge with a noninferiority limit of 24 hours. A sample size of 132 was needed to achieve 80% power with a 2-tailed alpha of 0.05. Intent-to-Treat and Per Protocol analyses were performed. Prespecified secondary outcomes included the need for additional antihypertensives, side effects, medication discontinuation, breastfeeding satisfaction, and readmission rate. A post-hoc analysis of time from medication initiation until hospital discharge was also performed. RESULTS: From April 2021 to December 2022, 7618 patients were screened and 175 patients were randomized, with 132 meeting criteria for antihypertensive initiation. Baseline demographics were similar between groups. Amlodipine had a non-inferior length of stay compared to nifedipine ER (Intent-to-Treat Wilcoxon pseudo-median amlodipine=73.5 hours, nifedipine ER=72.0 hours, 95% CI -8.00 to 6.00). The remainder of analyses were performed only on the Per Protocol cohort. Time from medication initiation until hospital discharge was similar between groups (amlodipine=45.0 hours, nifedipine ER=45.5 hours, 95% CI -8.00 to 13.00). There were no differences in use of additional antihypertensives or patient-reported side effects or breastfeeding outcomes, but hypotension and tachycardia were less common with amlodipine use. Amlodipine was significantly less likely to be discontinued due to side effects (amlodipine n=0, nifedipine ER n=7 (10.1%), p=.02). Readmission rates were similar between groups. CONCLUSION: Amlodipine is noninferior to nifedipine ER for postpartum hypertension treatment, as defined by median length of postpartum stay. Rates of side effects were similar between groups, but there was a statistically significant difference in medication discontinuation rates. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, www. CLINICALTRIALS: gov, NCT04790279 El resumen está disponible en Español al final del artículo.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Pratt K, Lordo R, Self S, et al. Amlodipine versus nifedipine ER for the management of postpartum hypertension: a noninferiority randomized controlled trial. Am J Obstet Gynecol MFM. 2024. PMID: 39662698. doi:10.1016/j.ajogmf.2024.101575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。